Pfizer and Allergan agree mega merger
23 November 2015 | By Victoria White
The combined company, to be named Pfizer plc, will be the biggest drug maker in the world by sales...
List view / Grid view
News
NICE draft guidance recommends elosulfase alfa for MPS IVa
23 November 2015 | By Victoria White
The positive draft guidance follows the development of a managed access scheme by BioMarin and NHS England...
FDA approves Ninlaro for multiple myeloma
23 November 2015 | By Victoria White
Ninlaro (ixazomib) is the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma...
Novartis’ secukinumab gains two landmark EU approvals
23 November 2015 | By Victoria White
The EC has approved secukinumab (Costenyx) for the treatment of people living with ankylosing spondylitis and psoriatic arthritis...
Researchers say Orphan Drug loophole needs to be addressed
20 November 2015 | By Victoria White
Health experts are calling on lawmakers to close loopholes in the Orphan Drug Act that, they claim, give drug companies millions of dollars in unintended and misplaced subsidies and tax breaks...
HORIBA Scientific announces new Product Line Manager for Optical Spectroscopy Division
20 November 2015 | By HORIBA Scientific
HORIBA Scientific, global leader in spectroscopic solutions, is pleased to announce that Francis Ndi, current Export Manager, has been promoted to Product Line Manager for the Optical Spectroscopy Division (OSD)...
Baxalta to initiate clinical trial of BAX 826 in haemophilia A
20 November 2015 | By Victoria White
Baxalta expects to begin treating participants in the open-label, dose-finding study by early 2016...
EC grants marketing authorisation for cystic fibrosis drug Orkambi
20 November 2015 | By Victoria White
Orkambi (lumacaftor/ivacaftor), authorised for use in patients who have two copies of the F508del mutation, is the first medicine to treat the underlying cause of cystic fibrosis...
Benepali receives positive opinion from CHMP
20 November 2015 | By Victoria White
Previously known as SB4, Benepali (etanercept) is a biosimilar candidate to the reference product Enbrel...
EC grants marketing authorisation to Kyprolis in multiple myeloma
20 November 2015 | By Victoria White
The announcement makes Kyprolis (carfilzomib) the first irreversible proteasome inhibitor approved in the EU for use in combination treatment of patients with relapsed multiple myeloma.
New data shows potential of ALS-008176 in RSV
19 November 2015 | By Victoria White
In the study, treatment with ALS-00876 resulted in a significant reduction of viral load and faster viral clearance versus placebo...
Cancer Drugs Fund public consultation launched
19 November 2015 | By Victoria White
The new Cancer Drugs Fund will become an instrument for the collection of important information on longer term benefits which may not be available at the time of licensing...
Atopic dermatitis treatment market to more than double in value
19 November 2015 | By Victoria White
The global atopic dermatitis treatment market will more than double in value from $3.6 billion in 2014 to an estimated $7.3 billion by 2024, according to research and consulting firm GlobalData.
NICE recommends Xofigo (radium-223) for prostate cancer
19 November 2015 | By Victoria White
NICE’s FAD coincides with a period of great uncertainty with the Cancer Drugs Fund deliberating again whether to remove radium-223 from the list...
Phase III study to evaluate pemetrexed and pembrolizumab in NSCLC
19 November 2015 | By Victoria White
Lilly and Merck are to evaluate the safety and efficacy of the combination of pemetrexed and pembrolizumab in a Phase III study in non-squamous NSCLC...
